ALZAMEND NEURO, INC. Proceeds from Issuance of Convertible Preferred Stock
ALZAMEND NEURO, INC. (ALZN) reported Proceeds from Issuance of Convertible Preferred Stock of $7.35 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2026-09-10
- ALZAMEND NEURO, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2026-07-31 was $7.35M, a 82.16% increase year-over-year.
- ALZAMEND NEURO, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2025-07-31 was $4.04M, a 105.49% increase year-over-year.
- ALZAMEND NEURO, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2024-07-31 was $1.96M.
- ALZAMEND NEURO, INC. proceeds from issuance of convertible preferred stock for fiscal 2026 was $4.04M, a 47.84% decline from fiscal 2025.
- ALZAMEND NEURO, INC. proceeds from issuance of convertible preferred stock for fiscal 2025 was $7.74M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|
| 2026-07-31 | $7.35M 10-Q · filed 2026-09-10 | |
| 2026-04-30 | $4.04M 10-K · filed 2026-07-22 | |
| 2025-07-31 | $4.04M 10-Q · filed 2026-09-10 | |
| 2025-04-30 | $7.74M 10-K · filed 2026-07-22 | |
| 2024-07-31 | $1.96M 10-Q · filed 2025-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |